The USPTO has allowed multiple claims Telcare under its pending US patent application covering the company’s cellular-enabled blood glucometer, the company has announced.

Said patent claims address two areas, the first of which is the engineering steps that must be taken to prevent the radio from interfering with the accuracy of the blood glucose measurement. The second area addressed is preventing the glucometer components from interfering with the cellular radio, which is critical to the meter’s data transmission and two-way messaging capabilities.

By safeguarding the integrity of blood glucose readings, Telcare’s tech is able to deliver accurate, sensitive medical data to patients and providers in near-real time. Paired with robust analytic capabilities, Telcare is able to transform raw patient data into timely insights for engaging patients and promoting improved care.

“Our glucometer is at the center of a much broader solution set focused on improving the lives of people living with diabetes,” said Andrew Flanagan, Telcare’s CEO. “We have a long history of trusted technology credentials and securing the allowance for this patent is just one example of what is ahead for Telcare.”

The technology granted in the patent allowance is already available in Telcare’s blood glucometer.